Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The prostate-specific membrane antigen (PSMA) has emerged as an interesting target for radionuclide therapy of metastasized castration-resistant prostate cancer (mCRPC). The aim of this study was to investigate 161 Tb (T 1/2 = 6.89 days; Eβ ͞ av = 154 keV) in combination with PSMA-617 as a potentially more effective therapeutic alternative to 177 Lu-PSMA-617, due to the abundant co-emission of conversion and Auger electrons, resulting in an improved absorbed dose profile. 161 Tb was used for the radiolabeling of PSMA-617 at high specific activities up to 100 MBq/nmol. 161 Tb-PSMA-617 was tested in vitro and in tumor-bearing mice to confirm equal properties, as previously determined for 177 Lu-PSMA-617. The effects of 161 Tb-PSMA-617 and 177 Lu-PSMA-617 on cell viability (MTT assay) and survival (clonogenic assay) were compared in vitro using PSMA-positive PC-3 PIP tumor cells. 161 Tb-PSMA-617 was further investigated in therapy studies using PC-3 PIP tumor-bearing mice. 161 Tb-PSMA-617 and 177 Lu-PSMA-617 displayed equal in-vitro properties and tissue distribution profiles in tumor-bearing mice. The viability and survival of PC-3 PIP tumor cells were more reduced when exposed to 161 Tb-PSMA-617 as compared to the effect obtained with the same activities of 177 Lu-PSMA-617 over the whole investigated concentration range. Treatment of mice with 161 Tb-PSMA-617 (5.0 MBq/mouse and 10 MBq/mouse, respectively) resulted in an activity-dependent increase of the median survival (36 vs 65 days) compared to untreated control animals (19 days). Therapy studies to compare the effects of 161 Tb-PSMA-617 and 177 Lu-PSMA-617 indicated the anticipated superiority of 161 Tb over 177 Lu. 161 Tb-PSMA-617 showed superior in-vitro and in-vivo results as compared to 177 Lu-PSMA-617, confirming theoretical dose calculations that indicate an additive therapeutic effect of conversion and Auger electrons in the case of 161 Tb. These data warrant more preclinical research for in-depth investigations of the proposed concept, and present a basis for future clinical translation of 161 Tb-PSMA-617 for the treatment of mCRPC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
Kratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191395 · Cited by 505
Development of 225Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences
Robertson, A. K. H., Ramogida, C. F., Schaffer, P., & Radchenko, V. (2018) · Current Radiopharmaceuticals · doi:10.2174/1874471011666180416161908 · Cited by 202
Cited by
Auger electrons for cancer therapy – a review
Ku, A., Facca, V. J., Cai, Z., & Reilly, R. M. (2019) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-019-0075-2 · Cited by 643
Potent candidates for Targeted Auger Therapy: Production and radiochemical considerations
Filosofov, D., Kurakina, E., & Radchenko, V. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2020.12.001 · Cited by 341
Advancements in the use of Auger electrons in science and medicine during the period 2015–2019
Howell, R. W. (2023) · International Journal of Radiation Biology · doi:10.1080/09553002.2020.1831706 · Cited by 274
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
Bakht, M. K., & Beltran, H. (2025) · Nature Reviews Urology · doi:10.1038/s41585-024-00900-z · Cited by 158
Mattana, F., Muraglia, L., Barone, A., Colandrea, M., Saker Diffalah, Y., Provera, S., Cascio, A. S., Omodeo Salè, E., & Ceci, F. (2024) · Cancers · doi:10.3390/cancers16091643 · Cited by 16
Metadata
- Authors
- Müller, C., Umbricht, C. A., Gracheva, N., Tschan, V. J., Pellegrini, G., Bernhardt, P., Zeevaart, J. R., Köster, U., Schibli, R., & van der Meulen, N. P.
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2019-05-27
- Volume
- 46
- Issue
- 9
- Pages
- 1919-1930
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W2947948130
- Cited by
- 230
- References
- 3
- FWCI
- 12.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.